Literature DB >> 31646296

Type 1 diabetes mellitus and coronary revascularization.

Helene Mamet1, Mark C Petrie1,2, Paul Rocchiccioli1.   

Abstract

Over the last three decades, trials of coronary revascularization have taken into account whether populations did or did not have diabetes. What has not been considered is whether or not patients with diabetes in these studies have type 1 or type 2 diabetes. 'Diabetes' appears to be largely used as a synonym for type 2 diabetes. The number of patients with type 1 diabetes has not been reported in most trials. Many questions remain unanswered. Do patients with type 1 diabetes have the same response to various modes of revascularization as those with type 2 diabetes? We know type 2 diabetes affects coronary endothelial function and the coronary artery wall but to what extent does type 1 diabetes affect these? Any response to revascularization does not just depend on the coronary artery but also on the myocardium. How does type 1 diabetes affect the myocardium? To what extent do patients with type 1 diabetes have viable or ischaemic myocardium or scar? What does 'diabetic cardiomyopathy' refer to in the context of type 1 diabetes? This manuscript reviews the evidence for revascularization in type 1 diabetes. We conclude that there has been a near absence of investigation of the pros and cons of revascularization in this population. Investigations to establish both the nature and extent of coronary and myocardial disease in these populations are necessary. Clinical trials of the pros and cons of revascularization in type 1 diabetes are necessary; many will declare that these will be too challenging to perform.
Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Keywords:  coronary; diabetes; revascularization

Year:  2019        PMID: 31646296      PMCID: PMC6739890          DOI: 10.1097/XCE.0000000000000166

Source DB:  PubMed          Journal:  Cardiovasc Endocrinol Metab        ISSN: 2574-0954


  23 in total

1.  Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: insights from the Arterial Revascularization Therapy Study (ARTS) trial.

Authors:  A Abizaid; M A Costa; M Centemero; A S Abizaid; V M Legrand; R V Limet; G Schuler; F W Mohr; W Lindeboom; A G Sousa; J E Sousa; B van Hout; P G Hugenholtz; F Unger; P W Serruys
Journal:  Circulation       Date:  2001-07-31       Impact factor: 29.690

2.  Glycemic Control, Cardiac Autoimmunity, and Long-Term Risk of Cardiovascular Disease in Type 1 Diabetes Mellitus.

Authors:  Giovane R Sousa; David Pober; Alfonso Galderisi; HuiJuan Lv; Liping Yu; Alexandre C Pereira; Alessandro Doria; Mikhail Kosiborod; Myra A Lipes
Journal:  Circulation       Date:  2019-02-05       Impact factor: 29.690

3.  Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial.

Authors:  Akhil Kapur; Roger J Hall; Iqbal S Malik; Ayesha C Qureshi; Jeremy Butts; Mark de Belder; Andreas Baumbach; Gianni Angelini; Adam de Belder; Keith G Oldroyd; Marcus Flather; Michael Roughton; Petros Nihoyannopoulos; Jens Peder Bagger; Kenneth Morgan; Kevin J Beatt
Journal:  J Am Coll Cardiol       Date:  2010-02-02       Impact factor: 24.094

4.  Randomized trial of stents versus bypass surgery for left main coronary artery disease.

Authors:  Seung-Jung Park; Young-Hak Kim; Duk-Woo Park; Sung-Cheol Yun; Jung-Min Ahn; Hae Geun Song; Jong-Young Lee; Won-Jang Kim; Soo-Jin Kang; Seung-Whan Lee; Cheol Whan Lee; Seong-Wook Park; Cheol-Hyun Chung; Jae-Won Lee; Do-Sun Lim; Seung-Woon Rha; Sang-Gon Lee; Hyeon-Cheol Gwon; Hyo-Soo Kim; In-Ho Chae; Yangsoo Jang; Myung-Ho Jeong; Seung-Jea Tahk; Ki Bae Seung
Journal:  N Engl J Med       Date:  2011-04-04       Impact factor: 91.245

Review 5.  Novel Diabetes Drugs and the Cardiovascular Specialist.

Authors:  Naveed Sattar; Mark C Petrie; Bernard Zinman; James L Januzzi
Journal:  J Am Coll Cardiol       Date:  2017-05-30       Impact factor: 24.094

6.  Clinical and angiographic outcomes in diabetics from the ENDEAVOR IV trial: randomized comparison of zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease.

Authors:  Ajay J Kirtane; Rikesh Patel; Charles O'Shaughnessy; Paul Overlie; Brent McLaurin; Stuart Solomon; Laura Mauri; Peter Fitzgerald; Jeffrey J Popma; David E Kandzari; Martin B Leon
Journal:  JACC Cardiovasc Interv       Date:  2009-10       Impact factor: 11.195

7.  Impact of diabetes on 10-year outcomes of patients with multivessel coronary artery disease in the Medicine, Angioplasty, or Surgery Study II (MASS II) trial.

Authors:  Eduardo Gomes Lima; Whady Hueb; Rosa Maria Rahmi Garcia; Alexandre Costa Pereira; Paulo Rogério Soares; Desiderio Favarato; Cibele Larrosa Garzillo; Ricardo D'Oliveira Vieira; Paulo Cury Rezende; Myrthes Takiuti; Priscyla Girardi; Alexandre Ciappina Hueb; José A F Ramires; Roberto Kalil Filho
Journal:  Am Heart J       Date:  2013-06-15       Impact factor: 4.749

8.  The long-term impact of diabetes on graft patency after coronary artery bypass grafting surgery: a substudy of the multicenter Radial Artery Patency Study.

Authors:  Saswata Deb; Steve K Singh; Fuad Moussa; Hideki Tsubota; Dai Une; Alex Kiss; George Tomlinson; Mehdi Afshar; Ryan Sless; Eric A Cohen; Sam Radhakrishnan; James Dubbin; Leonard Schwartz; Stephen E Fremes
Journal:  J Thorac Cardiovasc Surg       Date:  2014-07-17       Impact factor: 5.209

9.  Strategies for multivessel revascularization in patients with diabetes.

Authors:  Michael E Farkouh; Michael Domanski; Lynn A Sleeper; Flora S Siami; George Dangas; Michael Mack; May Yang; David J Cohen; Yves Rosenberg; Scott D Solomon; Akshay S Desai; Bernard J Gersh; Elizabeth A Magnuson; Alexandra Lansky; Robin Boineau; Jesse Weinberger; Krishnan Ramanathan; J Eduardo Sousa; Jamie Rankin; Balram Bhargava; John Buse; Whady Hueb; Craig R Smith; Victoria Muratov; Sameer Bansilal; Spencer King; Michel Bertrand; Valentin Fuster
Journal:  N Engl J Med       Date:  2012-11-04       Impact factor: 91.245

10.  A randomized trial of therapies for type 2 diabetes and coronary artery disease.

Authors:  Robert L Frye; Phyllis August; Maria Mori Brooks; Regina M Hardison; Sheryl F Kelsey; Joan M MacGregor; Trevor J Orchard; Bernard R Chaitman; Saul M Genuth; Suzanne H Goldberg; Mark A Hlatky; Teresa L Z Jones; Mark E Molitch; Richard W Nesto; Edward Y Sako; Burton E Sobel
Journal:  N Engl J Med       Date:  2009-06-07       Impact factor: 91.245

View more
  3 in total

1.  The MEK inhibitor U0126 ameliorates diabetic cardiomyopathy by restricting XBP1's phosphorylation dependent SUMOylation.

Authors:  Tao Wang; Jinhua Wu; Wei Dong; Mengwen Wang; Xiaodan Zhong; Wenjun Zhang; Lei Dai; Yang Xie; Yujian Liu; Xingwei He; Wanjun Liu; Thati Madhusudhan; Hesong Zeng; Hongjie Wang
Journal:  Int J Biol Sci       Date:  2021-07-13       Impact factor: 6.580

2.  Long-term cardiovascular prognosis of patients with type 1 diabetes after myocardial infarction.

Authors:  Anne M Kerola; Anne Grete Semb; Markus Juonala; Antti Palomäki; Päivi Rautava; Ville Kytö
Journal:  Cardiovasc Diabetol       Date:  2022-09-06       Impact factor: 8.949

3.  Matrine Protects Cardiomyocytes Against Hyperglycemic Stress by Promoting Mitofusin 2-Induced Mitochondrial Fusion.

Authors:  Tong Xiao; Jie Huang; Yuan Liu; Yujie Zhao; Manman Wei
Journal:  Front Physiol       Date:  2021-02-03       Impact factor: 4.755

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.